| Isentress (raltegravir) / Merck (MSD) |
AMICI, NCT00488059: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients |
|
|
| Terminated | 4 | 29 | US | enfuvirtide [Fuzeon], Optimized background ARV, Integrase inhibitor | Hoffmann-La Roche, Trimeris | HIV Infections | 10/08 | 10/08 | | |
NCT00632970: Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals |
|
|
| Terminated | 4 | 6 | US | Raltegravir, Isentress, Lopinavir/Ritonavir, Kaletra, Truvada, Emtricitabine/Tenofovir disoproxil fumarate | George Washington University | HIV Infections | 02/10 | 06/10 | | |
NCT00782301: Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients |
|
|
| Withdrawn | 4 | 0 | US, Canada, Europe | maraviroc, Selzentry, etravirine | ViiV Healthcare, Pfizer | Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic | 02/10 | 02/10 | | |
CORAL, NCT00772590: Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response |
|
|
| Completed | 4 | 75 | RoW | Raltegravir, Hyper-immune Bovine Colostrum, raltegravir placebo, placebo, Hyper-immune Bovine Colostrum placebo, raltegravir and hyper-immune bovine colostrum, Raltegravir + hyper-immune bovine colostrum | Kirby Institute | HIV Infections | 03/10 | 06/11 | | |
NCT00752037: Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients |
|
|
| Completed | 4 | 30 | US | lopinavir/ritonavir and raltegravir, Kaletra, Isentress | Saint Michael's Medical Center, Abbott | HIV Infections | 04/10 | 06/10 | | |
| Completed | 4 | 16 | Europe | Raltegravir, Etravirine | Hospitales Universitarios Virgen del Rocío | HIV-1 Infection, HIV Infections | 10/10 | 01/11 | | |
| Completed | 4 | 60 | US | Kaletra + Isentress, Raltegravir, Lopinavir/ritonavir, Pre-study antiretroviral regimen, HAART | Emory University, Abbott, Merck Sharp & Dohme LLC | HIV Infections | 01/11 | 01/11 | | |
| Completed | 4 | 57 | Europe | raltegravir, N/P. | Germans Trias i Pujol Hospital | HIV Infections | 05/11 | 05/11 | | |
| Terminated | 4 | 10 | US | 3-drug anti-HIV therapy, Raltegravir, Isentress | University of Washington, Merck Sharp & Dohme LLC | Human Immunodeficiency Virus | 02/12 | 10/13 | | |
RAL-NPEP, NCT01087840: Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men |
|
|
| Completed | 4 | 120 | RoW | Raltegravir, Isentress, Tenofovir disoproxil fumarate/emtricitabine | Andrew Carr, Merck Sharp & Dohme LLC | HIV Prevention, HIV Infections | 05/12 | 07/12 | | |
| Completed | 4 | 52 | RoW | Raltegravir, Isentress, MK-0518 | St Vincent's Hospital, Sidney, Merck Sharp & Dohme LLC, Holdsworth House Medical Practice, The Alfred | HIV, Osteopenia, Osteoporosis, HIV Infections | 06/12 | 04/14 | | |
| Completed | 4 | 85 | US | Raltegravir, Isentris, Darunavir, Prezista, Ritonavir, Norvir, Tenofovir/Emtricitabine, Truvada | Dallas VA Medical Center, Merck Sharp & Dohme LLC, Tibotec Pharmaceutical Limited | HIV Infections | 10/12 | 12/12 | | |
NCT01173510: A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells |
|
|
| Withdrawn | 4 | 0 | NA | Raltegravir plus Truvada, Atripla | Community Research Initiative of New England, Merck Sharp & Dohme LLC | HIV Infections, Acquired Immune Deficiency Syndrome | 10/12 | 10/12 | | |
RAN, NCT00762892: Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients |
|
|
| Completed | 4 | 33 | US | Raltegravir and truvada, Truvada is tenofovir 300 mg and emtricitabine 200 mg, Atazanavir, Norvir and Truvada | The University of Texas Health Science Center, Houston, Merck Sharp & Dohme LLC | HIV Infections | 12/12 | 01/13 | | |
NCT00870363: A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy |
|
|
| Completed | 4 | 44 | US | maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), Selzentry, maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), Selzentry (maraviroc), efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)], Sustiva | University of California, Davis | HIV Infections | 04/13 | 04/13 | | |
| Completed | 4 | 16 | US | emtricitabine/tenofovir disoproxil fumarate, Truvada, Isentress, Kaletra | Henry Ford Health System, Merck Sharp & Dohme LLC | Human Immunodeficiency Virus | 05/13 | 05/13 | | |
HANDral, NCT01448486: A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV |
|
|
| Terminated | 4 | 6 | RoW | Raltegravir, Isentress | St Vincent's Hospital, Sydney, Merck Sharp & Dohme LLC | Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND) | 10/13 | 10/13 | | |
NCT00843713: Effect of Raltegravir on Endothelial Function in HIV-Infected Patients |
|
|
| Completed | 4 | 56 | US | raltegravir, Placebo | University of California, San Francisco, National Heart, Lung, and Blood Institute (NHLBI), Merck Sharp & Dohme LLC | HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections | 11/13 | 02/14 | | |
NCT01214759: Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP) |
|
|
| Completed | 4 | 103 | US | Truvada, Tenofovir 200mg/emtricitabine 300mg, Raltegravir, Isentress | The University of Texas Health Science Center, Houston, Merck Sharp & Dohme LLC, Gilead Sciences | HIV | 12/13 | 08/15 | | |
RAL-PEP, NCT01576731 / 2011-003799-35: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir |
|
|
| Completed | 4 | 240 | Europe | Tenofovir, Emtricitabine, Lopinavir/r, Tenofovir, Emtricitabine, Raltegravir | Hospital Clinic of Barcelona | HIV Infection | 07/14 | 07/14 | | |
TaISENWITCH, NCT01679964: Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study |
|
|
| Completed | 4 | 107 | RoW | Raltegravir switch, Isentress | Lin, Hsi-Hsun, M.D. | HIV Infection, Adverse Drug Reaction, Quality of Life | 02/15 | 02/15 | | |
NCT01285050: Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds |
|
|
| Completed | 4 | 20 | US | Antiretroviral therapy (ART), raltegravir, Isentress, Emtricitabine and tenofovir disoproxil fumarate, Truvada | Johns Hopkins University, National Institute on Drug Abuse (NIDA) | HIV Infection, Hepatitis C | 04/15 | 04/15 | | |
NCT01989910: Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients |
|
|
| Completed | 4 | 107 | RoW | Raltegravir, Isentress, Efavirenz, Stocrit | Taipei Veterans General Hospital, Taiwan | HIV-1 Infection | 12/15 | 12/17 | | |
| Terminated | 4 | 4 | Europe | raltegravir and atazanavir and ritonavir, Isentress (raltegravir), Reyataz (atazanavir), Norvir (ritonavir), tenofovir/emtricitabine and atazanavir and ritonavir, tenofovir/emtricitabine (Truvada), atazanavir (Reyataz), ritonavir (norvir) | Giovanni Di Perri, University of Turin, Italy, University of Milan | HIV Infection, Osteopenia | 12/16 | 12/16 | | |
| Completed | 4 | 45 | Europe | Raltegravir, Issentres, Efavirenz, Sustiva | Juan Macías | HCV Coinfection, HIV Infection | 01/17 | 01/17 | | |
